Unable to display image

 

4/11 Big Biotech Deal; Takeda Gets Velcade
Takeda Pays $8.8 Billion for Millennium Pharmaceuticals ... The $25–a–share deal represented a 53 percent premium to Millennium’s closing price on Wednesday and set off speculation that other biotechnology companies might be acquired at high valuations, particularly by foreign companies ... [ NY Times ]
See also> Takeda Faces Generic Threat Even With Millenium Buy [ Bloomberg ]
http://www.nytimes.com/2008/04/10/business/worldbusiness/10cnd-drug.html?_r=1&ref=health&oref=slogin
 
Avatar Posted by worldpharmanews 2 days ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: acute myeloid leukaemia
An international team of scientists has shed new light on how a mutation in a protein causes acute myeloid leukaemia (AML), a type of blood cancer. The findings have implications for our understandin read more
 
Avatar Posted by SMB 3 days ago (http://scientific-misconduct.blogspot.com)
Category: Corporate | Tags: preemption johnson and johnson fudge
Possible Fudged data, and shielding from lawsuits read more
 
 
 http://www.worldpharmanews.com/content/view/363/30/
 
http://www.pharmalot.com/2008/04/schering-plough-cutting-jobs-plants-to-save-15b/
 
http://www.worldpharmanews.com/content/view/361/27/
Merck, Singulair and FDA
http://www.worldpharmanews.net/Blogs/Merck_Singulair_and_FDA/
 
 
The Bayer Group once again considerably improved its sales and earnings in 2007
 http://www.worldpharmanews.com/content/view/313/31/
Bayer appeals invalidity ruling on its Yasmin® Patent
 
 
 



Planning your summer road trip? Check out AOL Travel Guides.


Go BackHomeGo Forward